Charles River Labs Shareholders Elect New Board Members and Approve Key Proposals

Details

held its Annual Meeting of Shareholders on May 8, 2024. Eleven directors were elected to serve until the 2025 Annual Meeting, with strong support from shareholders. The meeting also saw an advisory approval of the compensation of named executive officers, and the ratification of PricewaterhouseCoopers LLP as the independent auditors for fiscal 2024. However, a shareholder proposal by PETA to publish a report on non-human primates imported by the company was not approved.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.